Baidu
map

Otol Neurotol:顺铂诱导听力损失的COOL疗法

2021-01-03 AlexYang MedSci原创

外耳局部降温对顺铂引起的听力损失的易感性有保护作用。之前,有研究人员曾证明使用凉水耳道灌洗对顺铂诱导的听力损失有显著的保护作用。然而,该研究仅限于单次注射顺铂和急性期。最近,他们调查了在更长的时间段内

外耳局部降温对顺铂引起的听力损失的易感性有保护作用。之前,有研究人员曾证明使用凉水耳道灌洗对顺铂诱导的听力损失有显著的保护作用。然而,该研究仅限于单次注射顺铂和急性期。最近,他们调查了在更长的时间段内,使用两种冷却方法对耳道进行局部冷却,并反复注射顺铂的相关听力情况。

研究包括了24只豚鼠(12只雄性和12只雌性),并在顺铂给药前/后进行了听觉生理测试(8-32kHz时的听觉脑干反应和畸变产物耳声发射)。顺铂(4 mg/kg i.p.)分3次注射,每周一次,共12 mg/kg。当麻醉后,豚鼠的左耳暴露于凉水(22℃)、凉耳棒(15℃),或未冷却的作为sham对照。在每个剂量3天后和最后1次剂量1个月后对动物进行测试。在实验结束时,动物被安乐死并进行组织学评价。研究结果表明,与只使用顺铂的对照动物相比,接受冷处理动物的听力损失显著减少,毛细胞的存活率大大提高。另外,两种冷却方法之间没有显著差异。

外毛细胞损失比例成对比较

最后,研究人员指出,在使用顺铂期间对耳道进行局部降温可减轻听觉功能的损失和毛细胞的损失

原始出处:

James K Stanford, Drew S Morgan, Nicholas A Bosworth et al. Cool OtOprotective Ear Lumen (COOL) Therapy for Cisplatin-induced Hearing Loss. Otol Neurotol. Dec 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1737671, encodeId=2d1d1e3767177, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Mon Nov 22 00:36:03 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819922, encodeId=1a0d1819922ca, content=<a href='/topic/show?id=d27b10012eb5' target=_blank style='color:#2F92EE;'>#顺铂诱导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100127, encryptionId=d27b10012eb5, topicName=顺铂诱导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jul 23 11:36:03 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306607, encodeId=c21f130660e8a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jan 05 03:36:03 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913689, encodeId=0523913689d9, content=现在化疗药对比起来副作用太大了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Jan 04 19:35:12 CST 2021, time=2021-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1737671, encodeId=2d1d1e3767177, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Mon Nov 22 00:36:03 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819922, encodeId=1a0d1819922ca, content=<a href='/topic/show?id=d27b10012eb5' target=_blank style='color:#2F92EE;'>#顺铂诱导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100127, encryptionId=d27b10012eb5, topicName=顺铂诱导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jul 23 11:36:03 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306607, encodeId=c21f130660e8a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jan 05 03:36:03 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913689, encodeId=0523913689d9, content=现在化疗药对比起来副作用太大了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Jan 04 19:35:12 CST 2021, time=2021-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1737671, encodeId=2d1d1e3767177, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Mon Nov 22 00:36:03 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819922, encodeId=1a0d1819922ca, content=<a href='/topic/show?id=d27b10012eb5' target=_blank style='color:#2F92EE;'>#顺铂诱导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100127, encryptionId=d27b10012eb5, topicName=顺铂诱导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jul 23 11:36:03 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306607, encodeId=c21f130660e8a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jan 05 03:36:03 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913689, encodeId=0523913689d9, content=现在化疗药对比起来副作用太大了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Jan 04 19:35:12 CST 2021, time=2021-01-04, status=1, ipAttribution=)]
    2021-01-05 ysjykql
  4. [GetPortalCommentsPageByObjectIdResponse(id=1737671, encodeId=2d1d1e3767177, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Mon Nov 22 00:36:03 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819922, encodeId=1a0d1819922ca, content=<a href='/topic/show?id=d27b10012eb5' target=_blank style='color:#2F92EE;'>#顺铂诱导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100127, encryptionId=d27b10012eb5, topicName=顺铂诱导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jul 23 11:36:03 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306607, encodeId=c21f130660e8a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Jan 05 03:36:03 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913689, encodeId=0523913689d9, content=现在化疗药对比起来副作用太大了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Jan 04 19:35:12 CST 2021, time=2021-01-04, status=1, ipAttribution=)]
    2021-01-04 12346c4dm64暂无昵称

    现在化疗药对比起来副作用太大了

    0

相关资讯

JCO:西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂

头颈部鳞状细胞癌(HNSCC)是全球第七大最常见的恶性肿瘤,每年全球新增病例超过80万例。局部晚期(III-IV期)的HNSCC的治疗仍充满挑战。

Cancer:二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果

局部晚期头颈鳞状细胞癌(LAHNSCC)患者的5年总生存率(OS)仍为50%,从而强调了改善治疗的必要性。在回顾性研究中发现一种抗糖尿病药物二甲双胍可以改善HNSCC患者的生存。因此,本研究旨在进行一

Radiother Oncol:西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者

西妥昔单抗的放疗(RT)是不适合顺铂治疗的晚期头颈鳞状细胞癌(HNSCC)患者的一种选择。由于5年总生存率低于50%,因此在治疗性环境中测试PD-L1免疫检查点阻断(avelumab)与西妥昔单抗-R

Lancet Glob Health:低成本的口服节律化疗治疗复发性转移性头颈癌

美国国家综合癌症网络(NCCN)推荐的头颈部癌症患者的姑息治疗方案由于成本原因,在低收入和中等收入国家(LMIC)的适用性较低(不到1-3%)。在之前的2期研究中,接受节律化疗的头颈部癌症患者比接受静

Clin Cancer Res:顺铂诱导的严重神经毒性的临床和全基因组分析

顺铂是许多癌症的一线化疗药物,但会引起神经毒性,包括听力损失、耳鸣和周围感觉神经病变。然而,到目前为止还没有研究综合描述发生多种(>1种)严重神经毒性的风险因素。

Br J Cancer:顺铂治疗加速睾丸癌幸存者的血管老化

睾丸癌(TC)虽然仅占男性所有癌症的1%,却是影响15至35岁男性的最常见的实体瘤。根据疾病的分期,一般采取睾丸切除术或切除术结合放疗(RT)、铂类药物化疗(CT)的方式进行治疗。至顺铂(cispla

Baidu
map
Baidu
map
Baidu
map